Drug Trial Radar · NCT05908786
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
62
Actual
Start
Dec 5, 2023
Primary completion
Aug 27, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
Conditions
- Carcinoma, Hepatocellular
Interventions
AtezolizumabDrug
Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
BevacizumabDrug
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
TiragolumabDrug
Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
TobemstomigDrug
Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathologic Response (MPR) RateTime frame: At the time of surgery (up to 15 weeks)
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
University of Southern California (USC)
Los Angeles, California
University of California Los Angeles (UCLA) - Cancer Care - Santa Monica
Santa Monica, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Columbia University Medical Center
New York, New York
UT Southwestern Medical Center
Dallas, Texas
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Department of Internal Medicine III AKH and Medical University of Vienna
Vienna, Austria
Centre Georges Francois Leclerc (CGFL)
Dijon, France
Gustave Roussy
Villejuif, France
University Essen
Essen, Germany
Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin
Frankfurt, Germany
Hospital Universitario Fundacion Jimenez Diaz.
Madrid, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Imperial College London - Imperial Centre for Translational and Experimental Medicine (ICTEM)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.